<DOC>
	<DOCNO>NCT02500641</DOCNO>
	<brief_summary>Comparison effect Febuxostat Allopurinol Pulse Wave Velocity ( PWV ) 36 week treatment .</brief_summary>
	<brief_title>Intensive Urate Lowering Therapy Febuxostat Compared Allopurinol Cardiovascular Risk Patients With Gout</brief_title>
	<detailed_description />
	<mesh_term>Gout</mesh_term>
	<mesh_term>Allopurinol</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<mesh_term>Colchicine</mesh_term>
	<mesh_term>Febuxostat</mesh_term>
	<mesh_term>Uric Acid</mesh_term>
	<criteria>1 . Male female patient 18 year old ; 2 . History gout , flare free 4 week prior study entry 3 . History crystal ( joint liquid ) proven diagnosis anamnestic diagnosis gout accord Wallace el . Preliminary criterion classification acute arthritis primary gout ; Arthritis Rheum , 1977 4 . Naive ULT previously treat ULT , ULT treatment last 1 month prior study entry reason ULT interruption due safety concern . 5 . Patients study entry elevate serum urate level &gt; 8 mg/dl . 6 . Overall Cardiovascular ( CV ) risk factor base score propose Joint Task Force European Society Cardiology European Societies cardiovascular disease prevention clinical practice 5 15 % ( inclusive ) . Patients diabetes mellitus type 2 could include study CV risk score calculate â‰¤7 % . Allowed concomitant medication maintain stable last 2 week randomisation 1 . Severe chronic renal failure ( creatinine clearance &lt; 30 ml/min ) 2 . Hepatic failure 3 . Active liver disease hepatic dysfunction , define alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 2 time upper limit normal . 4 . Diabetes mellitus type1 5 . Lifethreatening comorbidity significant medical condition and/or condition would interfere treatment , safety compliance protocol 6 . Diagnosis , receive treatment malignancy ( exclude basalioma skin cancer ) previous 5 year 7 . Patients experience either myocardial infarction stroke 8 . Patients inflammatory base arthritis ( e.g . : rheumatoid arthritis , etc . ) 9 . Patients congestive heart failure , New York Heart Association ( NYHA ) Class III IV 10 . Patients untreated/uncontrolled thyroid function 11 . Patients clinically severe peripheral arterial disease 12 . Concomitant administration follow : azathioprine , mercaptopurine , theophylline , meclofenamate , sulfinpyrazone , trimethoprimsulfamethoxazole , cyclophosphamide , benzbromarone , pyrazinamide , captopril enalapril ( Allopurinol ) , tegafur , pegloticase tacrolimus . 13 . Hypersensitivity one active substance excipients 14 . Any contraindication febuxostat allopurinol ( reference summary product characteristic ) . 15 . Subject unable take either protocolrequired gout flare prophylactic medication ( NSAID colchicine ) due contraindication intolerance , e.g . hypersensitivity , active gastric ulcer disease , renal impairment and/or change liver enzymes 16 . Participation another trial investigational drug device within 30 day prior screen , prior treatment investigational product ( ) 17 . Women childbearing potential ( WOCBP ) , include perimenopausal woman menstrual period within 1 year , willing use highly effective method birth control throughout study period 4 week study completion define method result failure rate le 1 % per year . 18 . Severe psychiatric disorders/neurological disorder 19 . Severe concurrent pathology , include terminal illness ( cancer , AIDS , etc ) 20 . Abuse alcohol , analgesic , psychotropic drug 21 . Inability unwillingness , investigator 's opinion , follow study procedure 22 . Inability unwillingness issue inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Biological Markers</keyword>
	<keyword>Cardiovascular disease</keyword>
	<keyword>Humans</keyword>
	<keyword>Pulse Wave Velocity</keyword>
	<keyword>Cardiovascular risk factor</keyword>
	<keyword>Allopurinol</keyword>
	<keyword>Pulse Wave Analysis</keyword>
	<keyword>Thiazoles</keyword>
	<keyword>Inflammation</keyword>
	<keyword>Uric acid</keyword>
	<keyword>Febuxostat</keyword>
	<keyword>Oxidative stress</keyword>
	<keyword>Tumor Necrosis Factor</keyword>
	<keyword>Arthritis</keyword>
	<keyword>Hyperuricemia</keyword>
</DOC>